Variability of the impact of adverse events on physicians' decision making

BMC Medical Informatics and Decision Making

Volumn 14, Issue 1, 2014, Pages

  Cozmuta, Raluca ^a   Merkel, Peter A ^b   Wahl, Elizabeth ^c   Fraenkel, Liana ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SAN FRANCISCO   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Best worst scaling; Cyclophosphamide; Decision making; Drug toxicity; Rituximab; Vasculitis

Indexed keywords

ADULT; ADVERSE DRUG REACTION; ATTITUDE TO HEALTH; DECISION MAKING; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSICIAN; STANDARDS;

ADULT; DECISION MAKING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS;

EID: 84907987217     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-14-86     Document Type: Article

References (33)

1. Breast cancer screening: conflicting guidelines and medicolegal risk. Kachalia A, Mello MM, JAMA 2013 309 2555 2556 10.1001/jama.2013.7100 23722969
2. Grading quality of evidence and strength of recommendations. GRADE Working Group, BMJ 2004 328 1490 1497 15205295
3. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. Stone JH, Merkel PA, Spiera R, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, for the RAVE-ITN Research Group, N Engl J Med 2010 363 221 232 10.1056/NEJMoa0909905 20647199
4. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW, for the European Vasculitis Study Group, N Engl J Med 2010 363 211 220 10.1056/NEJMoa0909169 20647198
5. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I, Arthritis Rheum 2004 50 3580 3590 10.1002/art.20592 15529346
6. Choosing treatment for proliferative lupus nephritis. Balow JE, Arthritis Rheum 2002 46 1981 1983 10.1002/art.10466 12209498
7. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME, J Autoimmun 2008 30 90 98 10.1016/j.jaut.2007.11.013 18191544
8. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Boumpas DT, Austin HA, Balow JE, Vaughan EM, Yarboro CH, Klippel JH, Steinberg AD, Lancet 1992 340 741 745 10.1016/0140-6736(92)92292-N 1356175
9. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Cohen P, Pagnoux C, Mahr A, Arène JP, Mouthon L, Le Guern V, André MH, Gayraud M, Jayne D, Blöckmans D, Cordier JF, Guillevin L, French Vasculitis Study Group, Arthritis Rheum 2007 57 686 693 10.1002/art.22679 17471546
10. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group), Ann Intern Med 2009 150 670 680 10.7326/0003-4819-150-10-200905190-00004 19451574
11. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR, Arthritis Rheum 2005 52 2461 2469 10.1002/art.21142 16052573
12. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Fauci AS, Haynes BF, Katz P, Wolff SM, Ann Internal Med 1983 98 76 85 10.7326/0003-4819-98-1-76
13. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B, J Rheumatol 2008 35 100 105 17937462
14. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Ginzler EM, Dooley MA, Aranow C, Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB, N Engl J Med 2005 53 2219 2228
15. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF, Arthritis Rheum 2007 56 1263 1272 10.1002/art.22505 17393458
16. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R, Arthritis Rheum 2002 46 2121 2131 10.1002/art.10461 12209517
17. Review article: progress of treatment in ANCA-associated vasculitis. Jayne D, Nephrology 2009 14 42 48 10.1111/j.1440-1797.2009.01101.x 19335843
18. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European community systemic vasculitis clinical trials study group. Jayne DR, Rasmussen N, Mayo Clin Proc 1997 72 737 747 10.1016/S0025-6196(11)63594-5 9276602
19. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG, Arthritis Rheum 2010 62 222 233 10.1002/art.27233 20039413
20. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS, Arthritis Rheum 2002 46 1003 1013 10.1002/art.10138 11953978
21. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA, European Vasculitis Study Group (EUVAS), Ann Rheum Dis 2008 67 1004 1010 10.1136/ard.2007.071936 17911225
22. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis a 20-year followup study. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA Jr, Kwoh CK, Arthritis Rheum 1995 38 1120 1127 10.1002/art.1780380815 7639809
23. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ, Arthritis Rheum 2005 52 2761 2767 10.1002/art.21263 16142702
24. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D, Rheumatology 2006 45 1432 1436 10.1093/rheumatology/kel098 16632482
25. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener Granulomatosis. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC, Ann Intern Med 1996 124 477 484 10.7326/0003-4819-124-5-199603010-00003 8602705
26. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M, Rheumatology 2008 47 821 827 10.1093/rheumatology/ken071 18397955
27. Response styles in rating scales. van Herk H, Poortinga YH, Verhallen TMM, J Cross Cult Psychol 2004 35 346 360 10.1177/0022022104264126
28. Best-worst scaling: what it can do for health care research and how to do it. Flynn T, Louviere J, Peters T, Coast J, J Health Econ 2007 26 171 189 10.1016/j.jhealeco.2006.04.002 16707175
29. The MaxDiff/Web v6.0 Technical Paper, http://www.sawtoothsoftware.com/download/techpap/maxdifftech.pdf
30. Orme B, Hierarchical Bayes regression analysis: technical paper Sequim: Sawtooth Software 2003 Available from: http://www.sawtoothsoftware.com
31. Post Marketing Reviews, Rituximab (marketed as Rituxan): Progressive Multifocal Leukoencephalopathy (PML) 2007 Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm115974.htm
32. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag K, Winthrop KL, Curtis JR, Arthritis Care Res 2012 64 612 615 10.1002/acr.21564
33. PML and rheumatology: the contribution of disease and drugs. Molloy ES, Clevel Clin J Med 2011 78 Suppl 2 28 S32